More on 01801

- Summary
- Chart
- Profile
- Historical

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Friends, Peers and Foes (?): IVBIY, 6IB, LLY, HCM, 3NX (more...)

Jun 24, 2026 07:01 AM Ollin Biosciences raises $330M Series B for eye disease drug trials
Jun 24, 2026 07:00 AM Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026
Jun 21, 2026 08:00 PM Innovent begins Phase 3 trial of tri-specific antibody for myeloma
Jun 21, 2026 08:00 PM Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
Jun 8, 2026 04:30 AM 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
Jun 4, 2026 04:35 AM Innovent submits gastric cancer drug for China regulatory review
Jun 4, 2026 04:35 AM World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer an
Jun 2, 2026 08:00 AM Ollin Biosciences Announces Upcoming Presentations of 20-week Data from Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular
May 31, 2026 08:00 PM 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherap
May 31, 2026 08:00 PM 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
View All Articles

Entities mentioned with 01801

View All Entities